375 related articles for article (PubMed ID: 32515968)
1. PEGylated-PLGA Nanoparticles Coated with pH-Responsive Tannic Acid-Fe(III) Complexes for Reduced Premature Doxorubicin Release and Enhanced Targeting in Breast Cancer.
Hu F; Zhang R; Guo W; Yan T; He X; Hu F; Ren F; Ma X; Lei J; Zheng W
Mol Pharm; 2021 Jun; 18(6):2161-2173. PubMed ID: 32515968
[TBL] [Abstract][Full Text] [Related]
2. Enhanced cancer therapy with pH-dependent and aptamer functionalized doxorubicin loaded polymeric (poly D, L-lactic-co-glycolic acid) nanoparticles.
Saravanakumar K; Hu X; Shanmugam S; Chelliah R; Sekar P; Oh DH; Vijayakumar S; Kathiresan K; Wang MH
Arch Biochem Biophys; 2019 Aug; 671():143-151. PubMed ID: 31283911
[TBL] [Abstract][Full Text] [Related]
3. Na
Araste F; Abnous K; Hashemi M; Dehshahri A; Detampel P; Alibolandi M; Ramezani M
Eur J Pharm Sci; 2020 Feb; 143():105207. PubMed ID: 31870814
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin-loaded poly (lactic-co-glycolic acid) nanoparticles coated with chitosan/alginate by layer by layer technology for antitumor applications.
Chai F; Sun L; He X; Li J; Liu Y; Xiong F; Ge L; Webster TJ; Zheng C
Int J Nanomedicine; 2017; 12():1791-1802. PubMed ID: 28424550
[TBL] [Abstract][Full Text] [Related]
5. PEGylated Poly(α-lipoic acid) Loaded with Doxorubicin as a pH and Reduction Dual Responsive Nanomedicine for Breast Cancer Therapy.
Yang H; Shen W; Liu W; Chen L; Zhang P; Xiao C; Chen X
Biomacromolecules; 2018 Nov; 19(11):4492-4503. PubMed ID: 30346147
[TBL] [Abstract][Full Text] [Related]
6. Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance.
Zhang D; Kong YY; Sun JH; Huo SJ; Zhou M; Gui YL; Mu X; Chen H; Yu SQ; Xu Q
Int J Nanomedicine; 2017; 12():2081-2108. PubMed ID: 28356731
[TBL] [Abstract][Full Text] [Related]
7. Reversion of Multidrug Resistance by Co-Encapsulation of Doxorubicin and Metformin in Poly(lactide-co-glycolide)-d-α-tocopheryl Polyethylene Glycol 1000 Succinate Nanoparticles.
Shafiei-Irannejad V; Samadi N; Salehi R; Yousefi B; Rahimi M; Akbarzadeh A; Zarghami N
Pharm Res; 2018 Apr; 35(6):119. PubMed ID: 29671072
[TBL] [Abstract][Full Text] [Related]
8. Specific cellular internalization and pH-responsive behavior of doxorubicin loaded PLGA-PEG nanoparticles targeted with anti EGFRvIII antibody.
Eivazi N; Rahmani R; Paknejad M
Life Sci; 2020 Nov; 261():118361. PubMed ID: 32861796
[TBL] [Abstract][Full Text] [Related]
9. Increased Toxicity of Doxorubicin Encapsulated into pH-Responsive Poly(β-Amino Ester)-Functionalized MCM-41 Silica Nanoparticles.
Ávila-Ortega A; Carrillo-Cocom LM; Olán-Noverola CE; Nic-Can GI; Vilchis-Nestor AR; Talavera-Pech WA
Curr Drug Deliv; 2020; 17(9):799-805. PubMed ID: 32723272
[TBL] [Abstract][Full Text] [Related]
10. Biotin-Conjugated Multilayer Poly [D,L-lactide-co-glycolide]-Lecithin-Polyethylene Glycol Nanoparticles for Targeted Delivery of Doxorubicin.
Dai Y; Xing H; Song F; Yang Y; Qiu Z; Lu X; Liu Q; Ren S; Chen X; Li N
J Pharm Sci; 2016 Sep; 105(9):2949-2958. PubMed ID: 27209461
[TBL] [Abstract][Full Text] [Related]
11. Improving Chemotherapy Effectiveness: Utilizing CuS Nanoparticles Coated with AS1411 Aptamer and Chitosan for Targeted Delivery of Doxorubicin to Cancerous Cells.
Imanimoghadam M; Yaghoobi E; Alizadeh F; Ramezani M; Alibolandi M; Abnous K; Taghdisi SM
J Pharm Sci; 2024 Jul; 113(7):1865-1873. PubMed ID: 38342338
[TBL] [Abstract][Full Text] [Related]
12. Biodegradable PLGA implants containing doxorubicin-loaded chitosan nanoparticles for treatment of breast tumor-bearing mice.
Kefayat A; Vaezifar S
Int J Biol Macromol; 2019 Sep; 136():48-56. PubMed ID: 31195043
[TBL] [Abstract][Full Text] [Related]
13. Multifunctional PLGA Nanobubbles as Theranostic Agents: Combining Doxorubicin and P-gp siRNA Co-Delivery Into Human Breast Cancer Cells and Ultrasound Cellular Imaging.
Yang H; Deng L; Li T; Shen X; Yan J; Zuo L; Wu C; Liu Y
J Biomed Nanotechnol; 2015 Dec; 11(12):2124-36. PubMed ID: 26510307
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo evaluation of anti-nucleolin-targeted magnetic PLGA nanoparticles loaded with doxorubicin as a theranostic agent for enhanced targeted cancer imaging and therapy.
Mosafer J; Abnous K; Tafaghodi M; Mokhtarzadeh A; Ramezani M
Eur J Pharm Biopharm; 2017 Apr; 113():60-74. PubMed ID: 28012991
[TBL] [Abstract][Full Text] [Related]
15. Novel Core-Interlayer-Shell DOX/ZnPc Co-loaded MSNs@ pH-Sensitive CaP@PEGylated Liposome for Enhanced Synergetic Chemo-Photodynamic Therapy.
Ma J; Wu H; Li Y; Liu Z; Liu G; Guo Y; Hou Z; Zhao Q; Chen D; Zhu X
Pharm Res; 2018 Feb; 35(3):57. PubMed ID: 29423532
[TBL] [Abstract][Full Text] [Related]
16. Redox-Sensitive Poly(lactic-
Dhamija P; Mehata AK; Tamang R; Bonlawar J; Vaishali ; Malik AK; Setia A; Kumar S; Challa RR; Koch B; Muthu MS
Mol Pharm; 2024 Jun; 21(6):2713-2726. PubMed ID: 38706253
[TBL] [Abstract][Full Text] [Related]
17. Self-assembled nanoparticles of reduction-sensitive poly (lactic-co-glycolic acid)-conjugated chondroitin sulfate A for doxorubicin delivery: preparation, characterization and evaluation.
Wang XF; Ren J; He HQ; Liang L; Xie X; Li ZX; Zhao JG; Yu JM
Pharm Dev Technol; 2019 Jul; 24(6):794-802. PubMed ID: 30907676
[TBL] [Abstract][Full Text] [Related]
18. Multifunctional PLGA nanoparticles combining transferrin-targetability and pH-stimuli sensitivity enhanced doxorubicin intracellular delivery and in vitro antineoplastic activity in MDR tumor cells.
Scheeren LE; Nogueira-Librelotto DR; Mathes D; Pillat MM; Macedo LB; Mitjans M; Vinardell MP; Rolim CMB
Toxicol In Vitro; 2021 Sep; 75():105192. PubMed ID: 33984456
[TBL] [Abstract][Full Text] [Related]
19. Mn
Xi J; Da L; Yang C; Chen R; Gao L; Fan L; Han J
Int J Nanomedicine; 2017; 12():3331-3345. PubMed ID: 28479854
[TBL] [Abstract][Full Text] [Related]
20. Novel doxorubicin / folate-targeted trans-ferulic acid-loaded PLGA nanoparticles combination: In-vivo superiority over standard chemotherapeutic regimen for breast cancer treatment.
Helmy SA; El-Mofty S; El Gayar AM; El-Sherbiny IM; El-Far YM
Biomed Pharmacother; 2022 Jan; 145():112376. PubMed ID: 34749055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]